A BrightFocus Foundation-funded study found that even moderate alcohol use can cause changes in the brain that may accelerate Alzheimer’s disease, shedding new light on a possible modifiable risk factor for dementia.
BrightFocus-funded research offers new evidence of the importance of tau in the prediction of Alzheimer’s disease which could lead to ways to delay—or even stop—the disease from progressing.
Led by a BrightFocus grantee, a research team has developed a new marker of Alzheimer’s disease neurodegeneration in the blood, paving the way for a more accurate blood test to detect Alzheimer’s disease.
Molecule Found in Green Tea Can Break Up Alzheimer's-Causing Protein Tangles, BrightFocus Researcher Finds
Using a molecule found in green tea, an Alzheimer's Disease Research-funded team of biochemists has identified new molecules that can destroy protein tangles in the brain linked to Alzheimer's and related brain diseases.
A new BrightFocus-funded clinical trial is one of the first to study the benefits of exercise in protecting brain health specifically among older African Americans.
The U.S. Food and Drug Administration today approved Leqembi (lecanemab-irmb) via the Accelerated Approval pathway for the treatment of Alzheimer’s disease based on its ability to clear toxic amyloid from the brain. It is the only drug in the class of amyloid immunotherapies shown to slow cognitive decline and will be available during or before the week of Jan. 23, 2023.
A new blood test that could facilitate a more accurate diagnosis of Alzheimer’s during the initial phases of the disease is on the way—rooted in critical early support from Alzheimer’s Disease Research, a program of BrightFocus Foundation. Catching the disease as soon as possible offers affected individuals the greatest gift of all—more time to spend with loved ones and explore disease management and treatment options.
Clinical trial results released Nov. 29 for lecanemab, a drug targeting early Alzheimer’s disease, reported a moderate slowing of cognitive decline in patients by 25% through the removal of amyloid-beta (Aβ) in the brain.
Gael Chetelat, PhD, University of Caen-Normandy, France, was honored on Oct. 21, 2022, by Women’s Health Access Matters for her BrightFocus-funded project, “Sex Differences in Risk Profiles Across the Alzheimer’s Disease Continuum.”
A recent article coauthored by BrightFocus Vice President, Scientific Affairs Diane Bovenkamp, PhD, proposes a new way to narrow racial and ethnic disparities in Alzheimer’s research through the development of standardized electronic health records.